Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 10/20 | 0.64 |
| ▸ | CHRNA4 | P43681 | 10/20 | 0.64 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.64 |
| ▸ | CHRNB4 | P30926 | 6/20 | 0.60 |
| ▸ | CHRNA3 | P32297 | 6/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL649140 | 1.00 | CHRNB2 (0.64) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| Hydrochloric Acid SCHEMBL649849 | 0.98 | CHRNB2 (0.67) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| Hydrochloric Acid SCHEMBL649850 | 0.98 | CHRNB2 (0.67) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL30556707 | 0.84 | CHRNB2 (0.70) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL7681491 | 0.83 | CHRNB2 (0.68) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL928568 | 0.83 | CHRNB2 (0.55) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL2323489 | 0.82 | CHRNB2 (0.53) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL20858748 | 0.81 | CHRNB2 (0.62) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL17297895 | 0.80 | CHRNB2 (0.62) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL651797 | 0.79 | CHRNB2 (0.97) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102863441-A | Clic central nervous system active agents | ABBOTT LAB | 2013-01-09 | — | — | CN | claimed |
| EP-2298775-A1 | Diazabicyclic central nervous system active agents | Abbott Laboratories (US) | 2011-03-23 | — | — | EP | claimed |
| EP-2295437-A1 | Diazabicyclic central nervous system active agents | Abbott Laboratories (US) | 2011-03-16 | — | — | EP | claimed |
| CN-101935322-A | Diazabicyclic central nervous system active agents | ABBOTT LAB | 2011-01-05 | — | — | CN | claimed |
| CN-101357915-A | Diazabicyclic central nervous system active agents | ABBOTT LAB (US) | 2009-02-04 | — | — | CN | claimed |
| US-6809105-B2 | (CIS)-6-(3-PYRIDINYL)-3,6-DIAZABICYCLO(3.2.0) HEPTANE FOR EXAMPLE; ALZHEIMER'S DISEASE, PARKINSON'S DISEASE, ATTENTION DEFICIT HYPERACTIVITY DISORDER, DEPRESSION, NICOTINIC WITHDRAWAL SYNDROME, TOURETTE'S SYNDROME, AND SCHIZOPHRENIA | ABBOTT LABORATORIES | 2004-10-26 | — | — | US | claimed |
| US-20040186107-A1 | Diazabicyclic central nervous system active agents | ABBVIE INC. | 2004-09-23 | — | — | US | claimed |
| CN-1440410-A | Diazabicyclic central nervous system active agents | ABBOTT LAB (US) | 2003-09-03 | — | — | CN | claimed |
| US-20020019388-A1 | Diazabicyclic central nervous system active agents | ABBVIE INC. | 2002-02-14 | — | — | US | claimed |
| US-20200147243-A1 | LIGAND COMPOUND OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR AND APPLICATION THEREOF | BEIJING NORMAL UNIVERSITY (CN) | 2020-05-14 | — | — | US | disclosed |
| EP-3632918-A1 | LIGAND COMPOUND OF 7 NICOTINIC ACETYLCHOLINE RECEPTOR AND APPLICATION THEREOF | Beijing Normal University (CN) | 2020-04-08 | — | — | EP | disclosed |
| CN-102863441-A | Clic central nervous system active agents | ABBOTT LAB | 2013-01-09 | — | — | CN | disclosed |
| US-20120208820-A1 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | SCHRIMPF MICHAEL R (US) | 2012-08-16 | — | — | US | disclosed |
| US-8119635-B2 | Diazabicyclic central nervous system active agents | ABBOTT LABORATORIES (US) | 2012-02-21 | — | — | US | disclosed |
| US-6809105-B2 | (CIS)-6-(3-PYRIDINYL)-3,6-DIAZABICYCLO(3.2.0) HEPTANE FOR EXAMPLE; ALZHEIMER'S DISEASE, PARKINSON'S DISEASE, ATTENTION DEFICIT HYPERACTIVITY DISORDER, DEPRESSION, NICOTINIC WITHDRAWAL SYNDROME, TOURETTE'S SYNDROME, AND SCHIZOPHRENIA | ABBOTT LABORATORIES | 2004-10-26 | — | — | US | disclosed |
| US-20040186107-A1 | Diazabicyclic central nervous system active agents | ABBVIE INC. | 2004-09-23 | — | — | US | disclosed |
| CN-1440410-A | Diazabicyclic central nervous system active agents | ABBOTT LAB (US) | 2003-09-03 | — | — | CN | disclosed |
| EP-1284976-A2 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | Abbott Laboratories (US) | 2003-02-26 | — | — | EP | disclosed |
| US-20020019388-A1 | Diazabicyclic central nervous system active agents | ABBVIE INC. | 2002-02-14 | — | — | US | disclosed |
| WO-2001081347-A2 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | ABBOTT LABORATORIES (US) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208820-A1 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | GAP43, GABRE, CHRNA6 | CHRNB2 10/4885CHRNA4 11/4885CHRNA7 5/4885 |
| US-20020019388-A1 | Diazabicyclic central nervous system active agents | GAP43, GABRE, CHRNA6 | CHRNB2 11/4885CHRNA4 8/4885CHRNA7 6/4885 |
| US-20200147243-A1 | LIGAND COMPOUND OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR AND APPLICATION THEREOF | CHRNA7, CHRNG, CHRNE | CHRNB2 16/4885CHRNA4 13/4885CHRNA7 1/4885 |
| US-20040186107-A1 | Diazabicyclic central nervous system active agents | GAP43, GABRE, CHRNA6 | CHRNB2 11/4885CHRNA4 8/4885CHRNA7 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.